Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch

As the U.S. stock market navigates through a landscape marked by tariff discussions and Federal Reserve policy updates, investors are keeping a close eye on how these factors influence broader indices like the Dow Jones, S&P 500, and Nasdaq. Penny stocks may be a throwback term, but the opportunities they represent are far from old news. Typically referring to smaller or newer companies, these stocks present an underappreciated chance for growth at lower price points. When combined with strong balance sheets and solid fundamentals, they can offer upside without many of the risks often associated with this corner of the market.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.896	$6.46M	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$125.23M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.25	$10.23M	★★★★★★
Imperial Petroleum (NasdaqCM:IMPP)	$2.95	$89.18M	★★★★★★
Permianville Royalty Trust (NYSE:PVL)	$1.42	$46.86M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$2.78	$46.67M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.44	$25.01M	★★★★★☆
CBAK Energy Technology (NasdaqCM:CBAT)	$0.8975	$79.45M	★★★★★☆
Safe Bulkers (NYSE:SB)	$3.64	$384.4M	★★★★☆☆

Click here to see the full list of 712 stocks from our US Penny Stocks screener.

Let's dive into some prime choices out of the screener.

Cocrystal Pharma (NasdaqCM:COCP)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Cocrystal Pharma, Inc. is a biotechnology company dedicated to discovering and developing antiviral therapeutic treatments for serious and chronic viral diseases, with a market cap of $18.62 million.

Operations: Cocrystal Pharma, Inc. currently does not report any revenue segments.

Market Cap: $18.62M

Cocrystal Pharma, Inc., with a market cap of US$18.62 million, remains pre-revenue as it focuses on developing antiviral treatments. Recent announcements highlight promising safety results from its Phase 1 study of CDI-988, targeting norovirus and coronavirus infections. Despite having no debt and short-term assets exceeding liabilities, the company faces financial challenges with less than a year of cash runway based on current free cash flow. It is unprofitable with a negative return on equity but has reduced losses over five years by 18.2% annually. Analysts predict significant stock price appreciation despite expected earnings decline.

• Click to explore a detailed breakdown of our findings in Cocrystal Pharma's financial health report.
• Understand Cocrystal Pharma's earnings outlook by examining our growth report.

Tuniu (NasdaqGM:TOUR)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Tuniu Corporation is an online leisure travel company based in China with a market cap of $118.77 million.

Operations: The company generates revenue primarily from its travel services segment, which amounted to CN¥510.84 million.

Market Cap: $118.77M

Tuniu Corporation, with a market cap of $118.77 million, shows financial stability as its short-term assets of CN¥1.6 billion exceed both short and long-term liabilities. The company has more cash than debt and has reduced its debt-to-equity ratio to 0% over five years. Despite being unprofitable with a negative return on equity, Tuniu reported increased Q3 revenue of CN¥186 million and net income growth to CN¥44.45 million year-over-year. It completed a share buyback program worth $5.6 million, enhancing shareholder value while forecasting modest revenue growth for Q4 2024.

• Unlock comprehensive insights into our analysis of Tuniu stock in this financial health report.
• Explore Tuniu's analyst forecasts in our growth report.

Kandi Technologies Group (NasdaqGS:KNDI)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Kandi Technologies Group, Inc. designs, develops, manufactures, and commercializes electric vehicle products and parts in China and the United States with a market cap of $92.10 million.

Operations: The company generates revenue primarily from its Auto Manufacturers segment, which accounts for $118.13 million.

Market Cap: $92.1M

Kandi Technologies Group, with a market cap of US$92.10 million, faces challenges as it remains unprofitable, reporting a net loss of US$4.11 million for Q3 2024 compared to a net income the previous year. Despite this, Kandi's short-term assets of US$396.7 million comfortably cover its liabilities, and the company has more cash than debt. The management team is experienced with an average tenure of 3.4 years and has not diluted shareholders recently. Kandi completed a share buyback program repurchasing 1.7% of shares for US$3.69 million, aiming to enhance shareholder value amidst volatile share prices.

• Click here and access our complete financial health analysis report to understand the dynamics of Kandi Technologies Group.
• Understand Kandi Technologies Group's track record by examining our performance history report.

Make It Happen

• Unlock more gems! Our US Penny Stocks screener has unearthed 709 more companies for you to explore.Click here to unveil our expertly curated list of 712 US Penny Stocks.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com